Publications by authors named "Simona Simonetta"
The overall changes of ocular motility in Graves' orbitopathy (GO) are not easily quantifiable with the methods currently available, especially in clinical studies. The aim of the present study was to calculate parameters that quantify the changes of ocular motility in GO in relation to the Gorman score for diplopia. We studied 100 GO patients (Group 1) and 100 controls (Group 2).
View Article and Find Full Text PDFBackground: Preliminary studies have shown that rituximab (RTX) is effective in the treatment of active Graves' orbitopathy (GO).
Methods: We conducted a double-blind, randomized trial (European Clinical Trials Database [EudraCT] 2007-003910-33) to compare RTX with iv methylprednisolone (ivMP) in patients with active moderate to severe GO. Thirty-two patients were randomized to receive either ivMP (7.
Article Synopsis
- * A clinical activity score (CAS) at two weeks post-treatment was identified as a good predictor of treatment response, while optic disc swelling at diagnosis indicated a likelihood of unresponsiveness to iv-MP.
- * The research highlights that specific visual and clinical characteristics prior to treatment, such as high CAS and severely altered visual fields, were associated with a lower likelihood of benefiting from steroid treatment, with no major side effects reported.
Congenital iris ectropion associated with juvenile glaucoma.
J Pediatr Ophthalmol Strabismus
March 2009
Congenital iris ectropion is an uncommon malformation and no reports exist about the use of modern technologies in this pathology. The authors describe a case of unilateral and isolated congenital iris ectropion associated with juvenile glaucoma in a healthy and completely asymptomatic 6-year-old girl with an unusual form of anisocoria. Optical coherence tomography and confocal scanning laser tomography showed a progressive glaucomatous neuropathy.
View Article and Find Full Text PDFRituximab (RTX) has been shown in previous work to improve thyroid-associated ophthalmopathy (TAO), but very little data is available on the effects of RTX in the target tissues. We studied the effects of RTX on peripheral lymphocytes and on the intra-orbital infiltrates in one patient with severe TAO who was treated with two cycles of therapy. Intra-orbital tissues derived at decompression from 3 patients with moderate-severe and 1 with severe TAO, treated with standard immunosuppression, were studied as controls.
View Article and Find Full Text PDFIntroduction: Hyperthyroid Graves' disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO).
Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied.